Novartis (NYSE:NVS) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Novartis AG (NYSE:NVS – Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $152.75 and traded as low as $150.73. Novartis shares last traded at $151.3380, with a volume of 3,549,680 shares.

Top Novartis Stories

Here are a few of the latest stories about NVS:

  • Positive Sentiment: Novartis raised its combined peak-sales forecast for three blockbuster drugs to $18 billion, from $14 billion, strengthening the potential contribution of those medicines to future growth. CNBC article
  • Neutral Sentiment: The company still expects annual sales growth of 5% through 2031, indicating continued expansion, though the updated forecast extends the outlook by a year. Reuters article
  • Negative Sentiment: The 5% annual growth target is below the previous 5%–6% forecast through 2030. The reduced ambition prompted negative investor reaction and contributed to the decline in Novartis shares. Reuters article Seeking Alpha article

Analysts Set New Price Targets

Several equities analysts have issued reports on NVS shares. Deutsche Bank cut shares of Novartis from a “hold” rating to a “sell” rating in a research note on Friday, October 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Novartis in a report on Wednesday, October 28th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a report on Sunday, August 9th. The Goldman Sachs Group reiterated a “sell” rating on shares of Novartis in a research note on Monday, September 21st. Finally, Berenberg Bank cut their price target on shares of Novartis from $147.00 to $130.00 and set a “hold” rating for the company in a report on Friday, September 11th. Six research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.25.

Read Our Latest Report on Novartis

Novartis Stock Performance

The company has a market capitalization of $287.03 billion, a P/E ratio of 28.71, a P/E/G ratio of 2.93 and a beta of 0.40. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.70 and a current ratio of 0.88. The business’s fifty day simple moving average is $150.45 and its 200-day simple moving average is $152.75.

Novartis (NYSE:NVS – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.53 billion. During the same quarter last year, the business posted $2.25 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. As a group, equities analysts anticipate that Novartis AG will post 9.10 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novartis

A number of institutional investors have recently bought and sold shares of the stock. Fisher Asset Management LLC boosted its stake in shares of Novartis by 8.0% in the third quarter. Fisher Asset Management LLC now owns 16,762,528 shares of the company’s stock valued at $2,389,834,000 after buying an additional 1,239,150 shares during the period. Bank of America Corp DE increased its stake in Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock valued at $758,067,000 after acquiring an additional 413,778 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Novartis by 10.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 3,296,470 shares of the company’s stock worth $469,978,000 after buying an additional 316,302 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Novartis by 0.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock worth $365,308,000 after buying an additional 19,595 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Novartis by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock worth $347,649,000 after buying an additional 41,520 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Recommended Stories

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.